Business Wire

Yokogawa Releases Dynamic Real Time Optimizer, a New Solution in the OpreX Asset Operations and Optimization Family

11.10.2019 05:00:00 EEST | Business Wire | Press release

Share

Yokogawa Electric Corporation (TOKYO:6841) announces the release of Dynamic Real Time Optimizer, a solution in the OpreXTM Asset Operations and Optimization family. Using a combination of first principles simulation and multivariable predictive control technology, the Dynamic Real Time Optimizer software helps to optimize plant operations.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191010005009/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Operating window of Dynamic Real Time Optimizer (Graphic: Yokogawa Electric Corporation)

This integrated solution is based on Yokogawa’s advanced process control technologies and industry knowledge and simulation technologies developed by KBC Advanced Technologies Limited (KBC, CEO: Andrew Howell), a UK-based Yokogawa subsidiary. This solution enables plants to quickly respond to dynamically changing oil market and product market conditions and improve both productivity and profitability.

Development Background

Advanced process control systems improve product yield and reduce energy consumption by maintaining temperature, flow rate, pressure, and other process variables within a set range and keeping them as close as possible to their optimal values, even for production processes whose parameters are not easily controlled by conventional control systems. Such advanced control systems are increasingly used in facilities such as oil refineries, petrochemical plants, chemical plants, and natural gas liquefaction trains. Advanced control solutions are attracting considerable interest due to their high economic value.

Multivariable advanced control systems determine the optimal value for plant independent variables. The optimal values are calculated based on information such as feedstock quality and prices, product specifications and prices, and energy costs. In a dynamically changing market, an advanced control system optimizes the operation of a plant in real time based on changes in raw material properties, product demand, and operating conditions.

Using our advanced control technology and KBC’s industry knowledge and simulation technology, we are able to perform highly accurate dynamic real-time optimization using rigorous models, in response to dynamically changing plant and market conditions.

Features

Dynamic Real Time Optimizer calculates the optimal values for plant independent variables with a high level of accuracy and was developed based on KBC’s Petro-SIMTM process simulation platform, which includes functions for online use. This solution acquires data through online connections to control systems and plant information management systems (PIMSs) and carries out case study simulations to generate rigorous models and calculate additional inferred properties. Based on these models and operating conditions, the optimal values are calculated by applying mathematical programming*1, and implemented online by the advanced control system.

1. Multi-unit optimization based on simulations performed using rigorous models

With large-scale applications, advanced control systems need to be able to quickly process huge amounts of data. Advanced control and optimization systems must have the processing speed needed to calculate the optimal values for such large applications. However, commercially-available products today are only suitable for small- to medium-size applications and can only optimize the control of individual process units. Yokogawa’s Platform for Advanced Control and Estimation*2 is capable of high-speed processing and can collectively control large-scale applications across processes. Using this suite as its operating platform, Dynamic Real Time Optimizer achieves multi-unit optimization and control. Also, as it makes use of KBC’s simulation technologies, the Dynamic Real Time Optimizer software can obtain optimal values with high accuracy even with reaction processes that demonstrate non-linear characteristics.

2. Integrated solution with improved maintainability

The performance of advanced control and optimization systems tends to degrade over time due to changes in operating conditions, catalyst activity changes, and the aging of facilities. Dynamic Real Time Optimizer is designed to maintain advanced control performance even as a plant changes, by using an online Petro-SIM model. The structure of this solution makes it easy to maintain advanced control and optimization systems, thus enabling operators to achieve optimal performance with nearly no change in maintenance workload.

*1 A method for determining the appropriate approach within a given range of rules, using mathematical models and computers
*2 A software suite with the following functionality:
- Multivariable model predictive control (the control of multiple variables based on predictions made using models of the dynamic characteristics of plant responses)
- Soft sensing for estimating quality in real time based on temperature, flow rate, pressure, and other process values
- Customization of calculations

Major Applications

Advanced control of continuous plant processes in the oil, petrochemical, chemical, gas, and other industries

For more information

https://www.yokogawa.com/solutions/solutions/oprex/oprex-transformation/oprex-asset-operations-and-optimization/dynamic-real-time-optimizer-rt-op

About OpreX

OpreX is the comprehensive brand for Yokogawa’s industrial automation (IA) and control business. The OpreX name stands for excellence in the technologies and solutions that Yokogawa cultivates through the co-creation of value with its customers, and encompasses the entire range of Yokogawa’s IA products, services, and solutions. This brand comprises the following five categories: OpreX Transformation, OpreX Control, OpreX Measurement, OpreX Execution, and OpreX Lifecycle. Platform for Advanced Control and Estimation, an OpreX Asset Operations and Optimization family solution in the OpreX Transformation category, delivers operational excellence throughout an enterprise’s activities, from production through to supply chain optimization and risk and business management.

With this brand, Yokogawa will deliver integrated solutions that address specific needs and support its customers in their efforts to transform and grow their businesses.

About Yokogawa

Founded in 1915, Yokogawa engages in broad-ranging activities in the areas of measurement, control, and information. The industrial automation business provides vital products, services, and solutions to a diverse range of process industries including oil, chemicals, natural gas, power, iron and steel, and pulp and paper. With the life innovation business, the company aims to radically improve productivity across the pharmaceutical and food industry value chains. The test & measurement, aviation, and other businesses continue to provide essential instruments and equipment with industry-leading precision and reliability. Yokogawa co-innovates with its customers through a global network of 113 companies spanning 60 countries, generating US$3.6 billion in sales in FY2018. For more information, please visit www.yokogawa.com.

The names of corporations, organizations, products, services and logos herein are either registered trademarks or trademarks of Yokogawa Electric Corporation or their respective holders.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Yokogawa Electric Corporation
Public Relations, Integrated Communications Center
Yokogawa-pr@cs.jp.yokogawa.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 10:10:00 EEST | Press release

LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The

Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 10:00:00 EEST | Press release

Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 years, she has led global teams to achieve a 100% success rate from Phase 3 development through to FDA approval for multiple programs spanning oncology, immunology and respiratory medicine. In addition, she raised funds of around $400M as founder and CEO. Across her career she has contributed to 20 drug approvals, engaging

TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 10:00:00 EEST | Press release

Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network upgrades. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260803353435/en/ Adtran’s SDX 6400 Series is helping TOHKnet demonstrate how Japan’s operators can migrate to 50G PON without disrupting existing PON services. “As demand for digital services continues to grow, this trial is a key milestone for the future of fiber access in Jap

“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 10:00:00 EEST | Press release

The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the project continues to captivate audiences through its

Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer4.8.2026 10:00:00 EEST | Press release

Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, today announced a clinical collaboration and supply agreement with plans to initiate a Phase 1b study combining its lead investigational compound, rupitasertib, with Roche’s investigational compound giredestrant, a selective estrogen receptor degrader (SERD), for the treatment of ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer. Rupitasertib, is a first-in-class oral dual-node PI3K/AKT/mTOR (PAM) pathway inhibitor, which selectively inhibits S6K and AKT1/3. Rupitasertib was purposefully and rationally designed to target S6K for potent PAM inhibition and AKT1/3 to block the AKT compensatory feedback loop, while sparing AKT2 to avoid hyperglycemia, which we believe will lead to a superior efficacy and safety profile compared to other PAM pathway inhibitors. Under the terms of the agreement, Roche will s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye